Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mucosal Impedance Contour Rapidly Distinguished GERD, non-GERD, and Eosinophilic Esophagitis

Key clinical point: Mucosal impedance contour rapidly differentiated gastroesophageal reflux disease from non-GERD and eosinophilic esophagitis.

Major finding: The pattern of mucosal impedance along the esophageal axis varied significantly (P less than .01) among these three groups.

Study details: Prospective study of 69 patients (24 with GERD, 21 with eosinophilic esophagitis, and 24 with normal esophagogastroduodenoscopy) and an external validation cohort of 36 patients (28 with GERD and eight with eosinophilic esophagitis).

Disclosures: The National Institutes of Health funded the external validation analysis. Diversatek Healthcare, which patented the device together with Vanderbilt University, gave research funding to four coinvestigators, including the senior author. Dr. Patel and the other five coinvestigators reported having no conflicts of interest.

Citation:

Patel DA et al. Gastroenterology. 2019 Jan 31. doi: 10.1053/j.gastro.2019.01.253.